Work

Nose-to-Brain Co-delivery of Temozolomide and Ganoderma lucidum Spore Oil in a Microemulsion for Enhanced Glioblastoma Therapy

Year: 2026
Type: article
Abstract: Temozolomide (TMZ)-based chemotherapy for glioblastoma (GBM) is severely limited by the blood–brain barrier (BBB) and the highly immunosuppressive tumor microenvironment (TME). Ganoderma lucidum spore oil (GSO) has TME-remodeling capacity, but its efficient delivery to the brain remains challenging. Here, we developed a TMZ and GSO coloaded microemulsion (TMZ&GSO-MEs) optimized for intranasal nose-to-brain delivery. Using an “active ingredient-as-excipient” design, GSO partially replaced the conventional oil phase, resulting in a uniform nanoscale formulation (∼35 nm), high encapsulation efficiency (92.6%), and sustained release. TMZ&GSO-MEs significantly enhanced cellular uptake of both TMZ and GSO and exhibited superior antiproliferative activity in GL261 cells compared to free TMZ. In an orthotopic Luc-GL261 glioma model, intranasal administration of TMZ&GSO-MEs markedly suppressed tumor growth (inhibition rate 66.5%) and extended survival (25% of mice alive at day 60). Mechanistically, GSO reprogrammed the TME by increasing M1-type tumor-associated macrophages, CD8+ T cells, and activated dendritic cells, while decreasing M2-type macrophages and TGF-β1 and shifting serum cytokines toward a Th1-dominant profile. Notably, the formulation showed a favorable safety profile with no significant body weight loss or hepatorenal toxicity. Collectively, this nose-to-brain microemulsion integrates enhanced intracranial delivery, chemo-immunotherapeutic synergy, and reduced toxicity, offering a promising strategy for GBM therapy.
Source: ACS Omega
Language: English
Open Access status: gold
Estimated APC paid: $1,935
OpenAlex ID: W7236783276
FWCI:
Cites: 49
Cited by:
Related to: 10